Hemanext Inc.

Hemanext Inc. specializes in innovative solutions for transfusion medicine, primarily through its FDA-authorized Hemanext ONE system, which processes and stores red blood cells to enhance their functionality and viability during transfusions. Founded in 1997 in Lexington, US, Hemanext Inc. focuses on advancing transfusion medicine through its unique technology.

In July 2025, Hemanext Inc. raised USD 18. 9 million in Series B funding. Andrew Dunham serves as the CEO.

Hemanext Inc. specializes in innovative technology solutions for transfusion medicine, with its core product, Hemanext ONE, standing out as the first FDA-authorized system designed to process and store red blood cells (RBCs) while effectively mitigating storage lesions. This technology is pivotal in enhancing the quality, functionality, and viability of RBCs during storage, thereby optimizing the therapeutic impact of blood transfusions for patients. The end users of Hemanext’s offerings primarily include healthcare providers such as hospitals, blood banks, and transfusion centers across various geographical markets, including North America and Europe, where Hemanext ONE is CE marked for commercial distribution.

By focusing on the study of hypoxically stored RBCs, the company aims to provide healthcare systems with transformative solutions that improve patient outcomes and the overall standard of care in transfusions. Hemanext derives its revenue through direct sales of its Hemanext ONE system and associated services to healthcare providers, particularly within the blood processing and transfusion sectors. The company engages in B2B transactions, partnering with hospitals and blood banks to deliver its innovative blood storage technology. Revenue generation occurs through structured agreements that often include equipment sales along with ongoing service contracts for maintenance and support.

These agreements may also encompass training programs for healthcare professionals to ensure optimal usage of the technology. While specific pricing details for Hemanext ONE and related services are not disclosed, the company's revenue model reflects a commitment to providing high-value solutions that enhance transfusion practices and patient care. The company plans to use the funding from July 2025 to expand early access deployments across hospitals and blood centers in the U. S.

, collect transfusion data, and accelerate customer adoption.